Last reviewed · How we verify

NCT04191265

Cardiotoxicity of Aluminum Phosphide Poisoning; Tropinin and CKmb as Early Biomarkers

Status unknown Last updated 13 May 2020
What this trial tests

trial testing serum tropinin, serum CKmb in Cardiotoxicity in 60 participants. Status unknown.

Timeline
5 December 2019
Primary endpoint
5 June 2020
5 June 2020

Quick facts

Lead sponsorAssiut University
StatusStatus unknown
Study typeOBSERVATIONAL
Enrollment60
Start date5 December 2019
Primary completion5 June 2020
Estimated completion5 June 2020
Sites1 location across Egypt

Drugs / interventions tested

Conditions studied

Sponsor

Assiut University

Who can join

Eligibility, any sex, with Cardiotoxicity or Aluminum Phosphid Poisoning. Patients with the condition only — healthy volunteers not accepted.

Sponsor's own description

Aluminum phosphide (AlP) or rice tablet is a cheap pesticide. When it comes in contact with acid (gastric acid) or moisture, it releases phosphine (PH3) gas. The heart,lungs, liver are the main targets in acute Aluminum phosphide (AlP) poisoning. Most deaths occur due to cardiovascular toxicity.

Publications & conference data

No peer-reviewed publications indexed yet for this trial.

Verify or expand the search:

Other recruiting trials for Cardiotoxicity

Currently open trials in the same condition.

Other Assiut University trials

Trials by the same sponsor.

Verify against primary sources

Data sources for this page

Drug Landscape aggregates and links these public records for informational use only. Always verify against the primary source before clinical or regulatory decisions. Canonical URL: https://druglandscape.com/trial/NCT04191265.

Primary sources · FDA · ClinicalTrials.gov · EMA · SEC EDGAR · ChEMBL · Wikidata · full sourcing